SpeeDx
ASX:SXSydney, Australia· Est.
Australian multiplex PCR diagnostics company enabling rapid, resistance‑guided infectious disease testing.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Australian multiplex PCR diagnostics company enabling rapid, resistance‑guided infectious disease testing.
Infectious Disease Diagnostics
Technology Platform
Proprietary Plex PCR technology that uses Plex Zyme universal probes and Plex Plus double‑detection to enable high‑multiplex, single‑well qPCR assays for pathogen and resistance marker detection.
Opportunities
Expansion of multiplex panels into emerging pathogens and point‑of‑care cartridge formats; increasing demand for resistance‑guided therapy in STI management.
Risk Factors
Regulatory clearance timelines, competition from larger diagnostics firms, and potential reagent supply‑chain constraints.
Competitive Landscape
Competes with Cepheid, Roche, Abbott, BioFire (bioMérieux), and Quidel; differentiates through its high‑multiplex Plex Plus technology and integrated resistance‑guided testing.